Longevity, a relatively new investment category, had a breakthrough year in 2021, attracting more than $40 billion globally, a figure projected to grow to $600 billion by 2025. While research funding has traditionally targeted chronic diseases such as Type 2 diabetes, cardiovascular diseases, and Alzheimer’s, where risk increases with age, the field of aging science is focused on how we might prevent these chronic conditions in the first place. Longevity companies are leveraging emerging research on the underlying mechanisms of aging to develop products that extend health to match increased lifespans. With the current fragmentation and competition in this field, this invitation-only event will highlight the opportunities and challenges of investing in scientific longevity solutions, and identify where investment capital could accelerate progress and ensure access for the greatest number.